Roivant Sciences Ltd. (ROIV) earnings date
Feb 8, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q3 FY2027
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 41 days, typically, give or take 8 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q2 FY2027 | Mon, Nov 9, 2026 | before open | 40 | 8-K |
| Q1 FY2027 | Thu, Aug 6, 2026 | before open | 37 | 8-K |
| Q4 FY2026 | Wed, May 20, 2026 | before open | 50 | 8-K |
| Q3 FY2026 | Fri, Feb 6, 2026 | before open | 37 | 8-K |
| Q2 FY2026 | Mon, Nov 10, 2025 | before open | 41 | 8-K |
| Q1 FY2026 | Mon, Aug 11, 2025 | before open | 42 | 8-K |
| Q4 FY2025 | Thu, May 29, 2025 | before open | 59 | 8-K |
| Q3 FY2025 | Mon, Feb 10, 2025 | before open | 41 | 8-K |
What they guided beta
| Q2 FY2027 | "Brepocitinib met the primary and all key secondary endpoints in the Phase 3 CLARITY-1 and CLARITY-2 trials in non-infectious uveitis (NIU); sNDA submission for NIU expected in the first half of calendar year 2027" exhibit |
| Q2 FY2027 | "Priovant intends to file an sNDA for brepocitinib for the treatment of NIU in the first half of calendar year 2027 and expects topline data from the Phase 3 study in CS in calendar year 2028." exhibit |
| Q2 FY2027 | "Immunovant expects to report topline data across potentially registrational trials of IMVT-1402 in GD and MG in calendar year 2027." exhibit |
| Q2 FY2027 | "In calendar year 2028, topline data are expected for the potentially registrational trial of IMVT-1402 in CIDP." exhibit |
| Q2 FY2027 | "This decrease reflected lower costs for the IMVT-1402 study in cutaneous lupus erythematosus, which was discontinued in September 2026, the wind-down of batoclimab clinical trials and the timing of contract manufacturing costs." exhibit |
| Q1 FY2027 | "Commercial preparations for brepocitinib in dermatomyositis (DM) are progressing well and on track for launch by the end of September 2026; topline data from Phase 3 study in non-infectious uveitis (NIU) expected in the second half of calendar year 2026" exhibit |
| Q1 FY2027 | "First patients enrolled in the Phase 3 study of brepocitinib in cutaneous sarcoidosis (CS), with topline data expected in calendar year 2028; enrollment in Part 1 of the Phase 2b/3 study in lichen planopilaris (LPP) is progressing well" exhibit |
| Q1 FY2027 | "IMVT-1402 proof-of-concept trial in cutaneous lupus erythematosus (CLE) topline data expected in the second half of calendar year 2026; all clinical development timelines remain on track for IMVT-1402" exhibit |
| Q1 FY2027 | "Mosliciguat Phase 2 study in pulmonary hypertension associated with interstitial lung disease (PH-ILD) remains on track, with topline data expected in the second half of calendar year 2026" exhibit |
| Q1 FY2027 | "Priovant expects the commercial launch of brepocitinib in DM by the end of September 2026 and topline data from the Phase 3 study in NIU and Phase 3 study in CS in the second half of calendar year 2026 and calendar year 2028, respectively." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ROIV
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ROIV
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/ROIV/"><img src="https://veritasdata.dev/embed/ROIV.svg" alt="ROIV earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/ROIV/)
Script
<script async src="https://veritasdata.dev/embed/ROIV.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ROIV"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.